XML 36 R120.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Financial Instruments and Fair Value Measurements (Narrative) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 27, 2019
Dec. 28, 2018
Jul. 24, 2019
Dec. 11, 2017
Sep. 25, 2017
Aug. 31, 2014
Apr. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business Combination, Contingent Consideration, Liability, Current $ 57.8            
Business Combination, Contingent Consideration, Liability, Noncurrent 11.5            
Novartis 2015 and 2016              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business Combination, Contingent Consideration, Annual Payments 25.0            
Novartis, Subsequent to 2016 till FDA Approval              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business Combination, Contingent Consideration, Annual Payments 25.0            
Novartis, Subsequent to FDA Approval              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business Combination, Contingent Consideration, Potential Payment 25.0            
Silence Therapeutics [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Equity Securities, FV-NI     $ 5.0        
Unrealized Gain (Loss) on Investments (20.2)            
Maximum contingent payments for acquisition $ 563.0            
Questcor Pharmaceuticals, Inc.              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Discount rate 4.70%            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability $ 24.5 $ 76.2       $ 195.4  
InfaCare [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair value of contingent consideration upon acquisition [1]         $ 35.0    
Maximum contingent payments for acquisition         $ 345.0    
Ocera [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair value of contingent consideration upon acquisition [2]       $ 22.0      
Maximum contingent payments for acquisition       $ 75.0      
Debentures | 8.00% debentures due March 2023 | Level 2              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Stated interest rate 8.00%            
Debentures | 9.50% debentures due May 2022 | Level 2              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Stated interest rate 9.50%            
Senior Notes | 4.75% senior notes due April 2023              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Stated interest rate             4.75%
Senior Notes | 4.75% senior notes due April 2023 | Fair Value, Inputs, Level 1 [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Stated interest rate 4.75%            
Senior Notes | 5.75% senior notes due August 2022              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Stated interest rate           5.75%  
Senior Notes | 5.75% senior notes due August 2022 | Fair Value, Inputs, Level 1 [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Stated interest rate 5.75%            
Senior Notes | Ten Point Zero Percent Notes [Member] | Fair Value, Inputs, Level 1 [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Stated interest rate 10.00%            
Debentures | Four Point Eight Eight Percent Notes [Member] | Fair Value, Inputs, Level 1 [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Stated interest rate 4.875%            
Debentures | Five Point Five Percent Notes [Member] | Fair Value, Inputs, Level 1 [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Stated interest rate 5.50%            
Debentures | Five Point Six Two Five Percent Note | Fair Value, Inputs, Level 1 [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Stated interest rate 5.625%            
Carrying Value | Fair Value, Inputs, Level 1 [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Restricted cash $ 31.7 18.6          
Carrying Value | Fair Value, Inputs, Level 3              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Cash surrender value of life insurance 51.1 66.4          
Fair Value, Measurements, Recurring              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair value of contingent consideration upon acquisition 69.3 151.4          
Debt and equity securities held in rabbi trusts 30.6 33.1          
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1 [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair value of contingent consideration upon acquisition 0.0 0.0          
Debt and equity securities held in rabbi trusts 21.0 22.4          
Fair Value, Measurements, Recurring | Level 2              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair value of contingent consideration upon acquisition 0.0 0.0          
Debt and equity securities held in rabbi trusts 9.6 10.7          
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair value of contingent consideration upon acquisition 69.3 151.4          
Debt and equity securities held in rabbi trusts 0.0 0.0          
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3 | Stratatech [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability 29.0 53.7          
Fair Value, Measurements, Recurring | Stannsoporfin [Member] | Fair Value, Inputs, Level 3 | InfaCare [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Liabilities, Fair Value Adjustment 35.0            
Fair Value, Measurements, Recurring | MNK-6105 [Member] | Fair Value, Inputs, Level 3 | Ocera [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair value of contingent consideration upon acquisition 15.8 21.5          
Contingent Consideration | Fair Value, Measurements, Recurring | Total Acquisitions              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 69.3            
Nuclear Imaging              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Contingent consideration received, equity certificates 9.0 9.0          
Nuclear Imaging | Fair Value, Inputs, Level 3              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Contingent consideration received, equity certificates $ 18.9 $ 9.0          
[1]
During fiscal 2019, the Company recognized a full impairment of the IPR&D asset related to stannsoporfin of $113.5 million. During fiscal 2018, the Company reduced the contingent consideration liability related to this acquisition to zero through the recognition of a $35.0 million fair value adjustment. Refer to Note 13 and 21 for further information.
[2]
$1.9 million of the total consideration, net of cash was paid in fiscal 2018, subsequent to the Company's December 11, 2017 acquisition date.